CardiovascularTOPICALGeneric
NYSTAFORM
CLIOQUINOL; NYSTATIN
Standard Dose
10MG/GM;100,000 UNITS/GM
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary
Approval overview NYSTAFORM is listed in Drugs@FDA under application 050235 (NDA).
Marketing status: Discontinued Active ingredient CLIOQUINOL; NYSTATIN Form and strength OINTMENT;TOPICAL - 10MG/GM;100,000 UNITS/GM Sponsor BAYER PHARMS Submission history See approval history documents.
Structured Monograph
Clinical summary
Approval overview NYSTAFORM is listed in Drugs@FDA under application 050235 (NDA). Marketing status: Discontinued Active ingredient CLIOQUINOL; NYSTATIN Form and strength OINTMENT;TOPICAL - 10MG/GM;100,000 UNITS/GM Sponsor BAYER PHARMS Submission history See approval history documents.
Monitoring
- • Marketing status: Discontinued
Interaction Notes
- No interaction notes stored yet.